Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Capital Expenditures (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Capital Expenditures data on record, last reported at $41000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 18.0% year-over-year to $41000.0; the TTM value through Dec 2025 reached $918000.0, up 166.09%, while the annual FY2025 figure was $918000.0, 166.09% up from the prior year.
  • Capital Expenditures reached $41000.0 in Q4 2025 per TLSI's latest filing, down from $857000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $857000.0 in Q3 2025 and bottomed at -$67000.0 in Q2 2025.
  • Average Capital Expenditures over 4 years is $158076.9, with a median of $66000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: soared 842.86% in 2024, then plummeted 211.67% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at $204000.0 in 2022, then soared by 82.35% to $372000.0 in 2023, then tumbled by 86.56% to $50000.0 in 2024, then decreased by 18.0% to $41000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $41000.0 in Q4 2025, $857000.0 in Q3 2025, and -$67000.0 in Q2 2025.